
Dermatology
Latest News

Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years

No Risk Increase for VTE in 6 Months of Baricitinib Therapy for Alopecia Areata
Latest Videos

CME Content
More News

This analysis looked at a Hispanic patient cohort, systematically linking specific trichoscopic patterns with clinical outcomes related to scalp psoriasis.

This Month in Review summary includes a list of some of the most notable stories in the dermatology field from August 2025.

Discover how the LEADDerm meeting transforms dermatology through leadership, collaboration, and personal development.

This analysis highlights the global prevalence of HS and some of the most significant global variations in HS prevalence.

Multidisciplinary management and patient-centered care are critical for optimizing outcomes in complex or severe psoriasis cases.

This analysis suggests that this AI model effectively classifies skin irritation in patch tests, allowing for quicker and more accurate dermatologic assessments.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

These findings on teledermatology highlight its effectiveness as a potential solution for disparities in dermatology care within rural communities.

These data on roflumilast cream 0.3% highlight the medication’s efficacy and safety in pediatric patients aged 2 - 11 years.

This study compared the N-NAIL diagnostic tool to NAPSI, highlighting results among patients with nail psoriasis.

In this analysis, a variety of alternative therapies for hair loss, such as oils, stem cells, and laser treatments, were highlighted for their potential.

This review highlights phase 3 and long-term data on deucravacitinib therapy for patients with plaque psoriasis.

Oral supplementation with a novel dietary AGA-P supplement was shown to increase the clinical efficacy of pharmacological treatments for androgenic alopecia.
The investigators present pooled findings from the SUNSHINE and SUNRISE trials assessing secukinumab therapy for HS.

This study highlights a significant link between alopecia areata and autoimmune thyroid disease, assessing a large-scale and diverse population.

In this analysis, investigators looked at quality of life data among pediatric patients with atopic dermatitis in Sub-Saharan Africa.

In this analysis, evidence which supports a shift in clinical practice using Chinese herbal medicine was explored for atopic dermatitis.

This study highlights an approach to male pattern baldness using a topical dimethylglycine sodium salt (DMG-Na) and caffeine-containing shampoo.

This cohort study suggests that patients with HS treated with adalimumab have an increased risk of infection compared to those with psoriasis.

Laura Ferris, MD, PhD, reflects on her unexpected path to department chair as well as the lessons of her journey as a leader in academic medicine.

This analysis of patients with atopic dermatitis in the BIOREP registry spotlight the safety and efficacy of lebrikizumab therapy.

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

The G-EPOSS study demonstrated the long-term impacts of guselkumab on patients’ psoriasis symptoms, sexual impairment, and perceived stigmatization.

Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.

Meta-analysis finds omalizumab and remibrutinib most effective for chronic urticaria unresponsive to antihistamines; cyclosporine has greater risks.
































































